Merck & Co., Inc. (NYSE:MRK) ranks among the best magic formula stocks to invest in. On July 10, UBS reiterated its Buy ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

In June 2025, the FDA approved KEYTRUDA for perioperative use in adults with resectable, locally advanced head and neck ...

Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the development of medicines for respiratory diseases. Merck will pay $10 billion in ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.